Roivant Sciences (ROIV) FY2024 results: revenue $29 million, down 11.2% on the year

Roivant Sciences Ltd. (ROIV) reported revenue of $29 million for fiscal 2024, the year ended 31 March 2025, down 11.2% on the year before. Net income was -$172 million, and diluted earnings per share $-0.24. The figures are the company's own, from the 10-K it filed with the SEC on 29 May 2025.

Revenue

$29 million

-11.2% on the year

FY2020FY2024

Operating margin

-3453.3%

13746.9% a year earlier

FY2020FY2024

Net income

-$172 million

FY2020FY2024

Diluted EPS

-$0.24

FY2020FY2024

this yearthe year beforeHover a bar for its figure.

The year in brief

The four quarters: Q1 FY2024 · Q2 FY2024 · Q3 FY2024 · Q4 FY2024

Income statement (profit and loss)

$ million	FY2024	FY2023	FY2022	On the year
Revenue	29.1	32.7	31.5	-11.2%
Research and development	550	440	454	+25.1%
Selling, general and administrative	n/a	687	601
Operating income	-1,003	4,497	-907
Operating margin	-3453.3%	13746.9%	-2875.9%
Interest expense	n/a	34.8	28.0
Pre-tax income	-682	4,568	-885
Income tax	48.2	21.5	4.1	+124.0%
Effective tax rate	n/a	0.5%	n/a
Net income	-172	4,349	-1,009
Net margin	-592.0%	13294.2%	-3200.2%
Diluted EPS	-$0.24	$5.23	-$1.42

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	FY2024	FY2023	FY2022	On the year
Operating cash flow	-839	-765	-843
Capital expenditure	4.6	1.4	12.7	+232.8%
Free cash flow	-844	-767	-856
Free cash flow margin	-2905.2%	-2343.6%	-2715.1%
Cash from investing	-1,766	5,204	-44.3
Cash from financing	-1,220	419	499
Depreciation and amortisation	14.1	22.0	18.9	-36.1%
Share-based compensation	289	200	218	+44.8%
Buybacks	1,293	0.0	0.0
Diluted shares, weighted	725m	831m	713m	-12.7%
Shares outstanding at period end	696m	807m	760m	-13.7%

Balance sheet

$ million	FY2024	FY2023	FY2022	On the year
Shareholders' equity	4,688	5,969	1,158	-21.5%
Non-controlling interest	500	480	450	+4.1%
Redeemable equity	n/a	n/a	0.0
Debt	0.0	431	416
Operating lease liabilities	90.3	45.0	53.5	+100.6%
Finance lease liabilities	n/a	n/a	3.6
Other liabilities	159	298	309	-46.6%
Total liabilities and equity	5,437	7,222	2,390	-24.7%
Fixed assets	12.1	15.3	39.1	-21.3%
Intangible assets	n/a	138	145
Investments	2,171	0.0	n/a
Cash and equivalents	2,715	6,495	1,677	-58.2%
Receivables	n/a	53.5	30.4
Inventory	n/a	35.3	2.8
Other assets	538	486	496	+10.8%
Total assets	5,437	7,222	2,390	-24.7%

10-K for the year ended 31 March 2025, filed 29 May 2025: the filing.